公开(公告)号：EP3851126A1

公开(公告)日：2021-07-21

申请号：EP20216572.6

申请日：2004-05-20

申请人： ImmunoGen, Inc.

发明人： CHARI, Ravi V.J. ,  WIDDISON, Wayne C.

IPC分类号： A61K47/68 ,  A61P17/02 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/00 ,  A61P33/02 ,  A61P33/04 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61P43/00 ,  C07D498/16

摘要： New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

公开(公告)号：EP3609477A1

公开(公告)日：2020-02-19

申请号：EP18719973.2

申请日：2018-04-12

申请人： Université de Bourgogne ,  Institut National Superieur des Sciences Agronomiques de L'Alimentation et de L'Environment (AGROSUP Dijon)

发明人： RIEU, Aurélie ,  GUZZO, Jean ,  ASSIFAOUI, Ali ,  HEUMANN, Arnaud

IPC分类号： A61K9/50 ,  A61K47/36 ,  A61K35/747 ,  A61K35/745 ,  A61K45/06 ,  A61K36/06 ,  A23L29/00 ,  A61K9/16 ,  B01J13/02 ,  A23C9/123 ,  A61K35/00 ,  A61P31/00 ,  A61P31/04 ,  A61P33/04

公开(公告)号：EP2902024A1

公开(公告)日：2015-08-05

申请号：EP12885371.0

申请日：2012-09-27

申请人： Siegfried Rhein S.A. De C.V.

发明人： FIORE, Esteban Alejandro

IPC分类号： A61K31/4184 ,  A61K31/426 ,  A61P33/04 ,  A61P33/10

CPC分类号： A61K31/4184 ,  A61K9/2095 ,  A61K31/426 ,  A61K2300/00

摘要： The invention relates to a synergic pharmaceutical composition of mebendazole (MBDZ) with nitazoxanide (NTZX) for the treatment of human parasitosis, which significantly increases the spectrum of MBDZ against protozoa and reinforces the anthelmintic action of NTZX. Furthermore, when said pharmaceutical combination of MBDZ and NTZX is used, the same effects of the individual active substances are maintained in the systemic action of the active metabolite of NTZX, tizoxanide, and in the treatment of some systemic forms of parasitosis. In addition, the synergic pharmaceutical combination of MBDZ with NTZX achieves a larger anti-parasite spectrum, while maintaining the efficiency and safety profiles of both active substances independently. All of these effects enable the differentiation of the pharmaceutical combination from the rest of the conventional anti-parasite treatments that have more limited spectra. The invention therefore relates principally to the synergic effects of the pharmaceutical combination of MBDZ and NTZX.

公开(公告)号：EP1747002B1

公开(公告)日：2009-10-14

申请号：EP05745024.9

申请日：2005-05-13

申请人： Chemor Kutato, Fejleszto es Kereskedo Kft.

发明人： ORBÁN, Gyula

IPC分类号： A61K31/616 ,  A61P33/04

CPC分类号： A61K31/616

摘要： The invention relates to a veterinary composition for the treatment and/or prevention of the nosema disease (Nosemosis apium) at honey bees comprising 2-hidroxi-benzoic acid (salicylic acid) or 2-acetoxi-benzoic acid (acetyl­salicylic acid ) or their salt(s) as active ingredient. In a preferable variant the composition contains sugar-industry molasses (concentrated watery extract of Beta vulgaris cv altissima) as carrier and if desired any other known auxiliary and carrier substances.

公开(公告)号：EP1250142A4

公开(公告)日：2007-07-11

申请号：EP00973747

申请日：2000-10-20

申请人： MARANTECH HOLDING LLC

发明人： ANTELMAN MARVIN S

IPC分类号： A61K9/14 ,  A61K8/02 ,  A61K8/19 ,  A61K9/00 ,  A61K9/06 ,  A61K9/16 ,  A61K9/70 ,  A61K33/24 ,  A61K33/26 ,  A61K33/32 ,  A61K33/34 ,  A61K33/38 ,  A61K45/00 ,  A61K47/02 ,  A61K47/06 ,  A61K47/30 ,  A61K47/36 ,  A61K47/38 ,  A61K47/44 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/12 ,  A61P1/16 ,  A61P7/00 ,  A61P9/00 ,  A61P11/00 ,  A61P11/02 ,  A61P13/00 ,  A61P13/12 ,  A61P15/00 ,  A61P15/06 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P17/10 ,  A61P17/12 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/00 ,  A61P25/28 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/08 ,  A61P31/10 ,  A61P31/12 ,  A61P31/16 ,  A61P31/22 ,  A61P33/00 ,  A61P33/04 ,  A61P33/06 ,  A61P35/00 ,  A61P37/00 ,  A61P39/00 ,  A61Q1/12 ,  A61Q19/00 ,  C01G3/02 ,  A61K33/00

CPC分类号： A61K8/0208 ,  A61K8/19 ,  A61K9/0014 ,  A61K9/06 ,  A61K33/24 ,  A61K33/245 ,  A61K33/26 ,  A61K33/32 ,  A61K33/34 ,  A61K33/38 ,  A61K47/02 ,  A61Q1/12 ,  A61Q19/00 ,  C01G3/02

摘要： The present invention is directed to pharmaceutical compositions that include a therapeutically effective amount of at least one electron active compound, or a pharmaceutically acceptable derivative thereof, that has at least two polyvalent cations, at least one of which has a first valence state and at least one of which has a second, different valence state. Preferred compounds include Bi(III,V) oxide, Co(II,III) oxide, Cu(I,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, and Pr(III,IV) oxide, and optionally Ag(I,III) oxide. These compounds may be in a crystalline state having metallic cations of two different valences, or electronic states, in the inorganic crystal. In addition, the invention relates to methods for prevention, management, or treatment of a condition using these compounds or pharmaceutical compositions including the same.

公开(公告)号：EP1695715A1

公开(公告)日：2006-08-30

申请号：EP04802606.6

申请日：2004-11-10

申请人： Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros ,  Centro de Investigacion y de Estudios Avanzados del Instituto Politécnico Nacional

发明人： OROZCO OROZCO, Maria E., Via Ceti No. 20. ,  SIERRA GONZALEZ, Gustavo Victoriano ,  GARCIA MADRIZ, Xochil, Calle 15 No. 1306 ,  MARTINEZ BENITEZ, Máximo B., 5ta Ave., No. 18 ,  RODRIGUEZ RODRIGUEZ, Mario A., Deutz Hermanos, 31 ,  GARCIA RIVERA, G., Plazuela 2 de Plaza Sésamo ,  ACOSTA DOMINGUEZ, Armando

IPC分类号： A61K39/002 ,  C12N15/30 ,  C07K14/44 ,  A61P33/04

CPC分类号： A61K39/002 ,  A61K2039/53 ,  Y02A50/487

摘要： SUMMARY
This invention relates to the field of immunology, specifically to vaccinal compositions for the control of infections caused by Entamoeba histolytica.
The active principle of the compositions of the invention is a 112kDa amoebian surface protein, coded by two genes, one coding for a peptide with cystein protease activity and the other for a peptide with adhesin activity. The scope of the invention includes formulations containing the genes coding for said protein, which are administered as DNA vaccines and also formulations containing the purified proteins or fragments thereof, achieving a synergic effect as regards protection with the combination.
These formulations can be administered for prophylactic or therapeutical purposes to fight against the amoebian infection caused by the protozoan parasite Entamoeba histolytica.

摘要翻译： 发明内容本发明涉及免疫学领域，具体地涉及用于通过溶组织内阿米巴感染引起的控制的组合物疫苗。 在本发明组合物的活性成分是一种112kDa amoebian表面蛋白，由两个基因，一个编码与半胱氨酸蛋白酶活性的肽，而另一个用于与粘附活性的肽编码。 在本发明的范围包括式蒸发散含有编码所述蛋白质，其被施用DNA疫苗，因此含有纯化蛋白或其片段式蒸发散，实现如同与组合关于保护协同作用的基因。 这些式蒸发散可以施用用于预防或治疗目的，以抵抗由原生动物寄生虫溶组织内阿米巴引发的感染amoebian战斗。

公开(公告)号：EP1488800A4

公开(公告)日：2006-05-31

申请号：EP03715387

申请日：2003-03-20

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： SUZUKI HIROSHI

IPC分类号： A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K47/42 ,  A61P7/06 ,  A61P33/02 ,  A61P33/04 ,  A61P33/06 ,  A61K9/08

CPC分类号： A61K38/1816 ,  A61K9/0019 ,  A61K47/183 ,  A61K47/26 ,  A61K47/42

摘要： An EPO-containing pharmaceutical composition effective for the treatment of protozoal disease, a method for treatment of protozoal disease by administering EPO to a patient with protozoal disease, and use of EPO in producing an agent for treatment of protozoal disease are disclosed. Several medicines have been used for treatment of protozoal diseases, but these medicines have relatively high side effects. Pentamidine, in particular, has been considered to be effective against protozoal disease, but may develop severe hypotension, hypoglycemia and arrhythmia. In patients with disorder of the kidney or liver, pentamidine may aggravate impaired renal or hepatic function, and tends to show side effects. Pentamidine may also exacerbate the symptoms of patients with hypotension or hypertension, and patients with hypoglycemia or hyperglycemia. The present invention provides an agent for treatment of protozoal disease, the agent free from or minimal in such side effects.

公开(公告)号：EP1027070A4

公开(公告)日：2004-08-18

申请号：EP98953865

申请日：1998-10-22

申请人： SLOAN KETTERING INSTITUTEFOR C

发明人： ROTHMAN JAMES E ,  MAYHEW MARK ,  HOE MEE H ,  HOUGHTON ALAN ,  HARTL ULRICH ,  OUERFELLI OUATHEK ,  MOROI YOICHI

IPC分类号： C12N15/09 ,  A61K35/00 ,  A61K35/02 ,  A61K39/385 ,  A61K39/39 ,  A61K47/42 ,  A61K47/48 ,  A61P3/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/16 ,  A61P31/18 ,  A61P31/22 ,  A61P33/04 ,  A61P33/06 ,  A61P37/02 ,  A61P37/04 ,  C07K14/435 ,  C07K14/47 ,  C07K14/705 ,  C07K19/00 ,  C12N15/00 ,  A61K39/00

CPC分类号： C07K14/47 ,  A61K39/385 ,  A61K47/646 ,  A61K2039/6043 ,  A61K2039/622

摘要： The present invention relates (i) to conjugate peptides engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response tin a subject in need of such treatment. It is based, at least in part, on the discovery of tethering molecules which may be used to non-covalently link antigenic peptides to heat shock proteins. The present invention also provides for methods of identifying additional tethers which may be comprised, togethter with antigenic sequences, in conjugate peptides.

公开(公告)号：EP4362988A1

公开(公告)日：2024-05-08

申请号：EP22737960.9

申请日：2022-06-28

申请人： The University of Manchester

发明人： BROMLEY, Mike ,  VENDRELL ESCOBAR, Marc

IPC分类号： A61K49/00 ,  C07K7/06 ,  A61P31/04 ,  A61P31/10 ,  A61P33/04

CPC分类号： A61K49/0043 ,  A61K49/0032 ,  A61K49/0056 ,  C07K7/06 ,  A61P31/10 ,  A61P31/04 ,  A61P33/04 ,  C07K7/52

公开(公告)号：EP4218420A1

公开(公告)日：2023-08-02

申请号：EP21872942.4

申请日：2021-09-24

申请人： CJ Cheiljedang Corporation

发明人： SON, Kyuyeol ,  PARK, Min Ah ,  LEE, Kyung Min ,  KIM, Hwi-Jea

IPC分类号： A23K20/116 ,  A23K20/126 ,  A23K10/30 ,  A61K31/365 ,  A61K31/352 ,  A61P33/10 ,  A61P33/04

摘要： The present application relates to an anticoccidial composition comprising ginkgo leaves and use thereof. The composition comprising ginkgo leaves, according to an embodiment, has excellent effects of directly killing sporozoites that can induce coccidiosis, inhibiting the penetration of the sporozoites into cells, and/or inhibiting the proliferation of the sporozoites in cells, and has excellent effects of preventing, ameliorating and treating coccidiosis in vivo.